Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NIMOTOP vs ANOQUAN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Nimodipine is a dihydropyridine calcium channel blocker that selectively inhibits calcium influx into vascular smooth muscle cells, leading to vasodilation. It has a preferential effect on cerebral arteries, reducing the incidence of vasospasm following subarachnoid hemorrhage.
Guanabenz is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brain, leading to decreased peripheral vascular resistance and lowered blood pressure.
Improvement of neurological outcome by reducing the incidence and severity of ischemic deficits in patients with subarachnoid hemorrhage from ruptured intracranial berry aneurysms,Off-label: Prevention of cerebral vasospasm after subarachnoid hemorrhage, treatment of migraine, and cluster headaches
Hypertension
60 mg orally every 4 hours for 21 days, initiated within 96 hours of subarachnoid hemorrhage. If unable to swallow, 0.5 mg/h continuous IV infusion via central line; increase to 1 mg/h after 2 hours if tolerated, continue for up to 21 days.
100 mg orally twice daily
Terminal elimination half-life is approximately 8–9 hours (range 3–12 hours) in adults, with clinical context of twice-daily dosing for continuous cerebral vasodilation in subarachnoid hemorrhage.
Terminal elimination half-life is 12-15 hours in adults with normal renal function; prolonged to 24-48 hours in severe renal impairment (Cr Cl <30 m L/min).
Nimodipine is extensively metabolized in the liver primarily by the CYP3A4 isoenzyme, with no significant first-pass effect. Metabolites are excreted mainly in bile (about 80%) and urine (about 20%).
Hepatic metabolism via oxidation and conjugation; metabolites excreted renally.
Primarily hepatic metabolism; 50% excreted in urine as metabolites, 30% in feces via biliary elimination. Less than 1% excreted unchanged in urine.
Renal excretion accounts for approximately 70% of the dose (50% as unchanged drug, 20% as inactive metabolites); biliary/fecal excretion accounts for 30%.
97–99% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
Approximately 90% bound to albumin.
Volume of distribution is 0.9–1.6 L/kg (average 1.2 L/kg), indicating extensive tissue distribution and high lipophilicity.
0.8-1.2 L/kg, indicating extensive distribution into total body water.
Oral: 13% (range 3–30%) due to extensive first-pass metabolism. Intravenous: 100%.
Oral: 60-70% due to first-pass metabolism.
No dose adjustment required for renal impairment. Use caution in severe renal failure due to risk of accumulation of metabolites.
GFR 30-50 m L/min: 100 mg once daily; GFR <30 m L/min: 50 mg once daily; not recommended for GFR <15 m L/min
Contraindicated in severe hepatic impairment (Child-Pugh C). In mild to moderate (Child-Pugh A or B), reduce oral dose to 30 mg every 4 hours or decrease IV infusion rate to 0.5 mg/h; monitor blood pressure closely.
Child-Pugh A: no adjustment; Child-Pugh B: 50 mg twice daily; Child-Pugh C: not recommended
Safety and efficacy not established in pediatric patients; no recommended dosing.
Not approved for pediatric use; no established dosing
No specific dose adjustment required, but elderly patients may be more sensitive to hypotensive effects; monitor blood pressure closely and consider starting at lower end of dosing range.
No specific adjustment; monitor renal function and consider reduced initial dose (50 mg twice daily) in patients >65 years with renal impairment
No FDA black box warning.
No FDA black box warning.
Hypotension: May cause systemic hypotension, especially in patients with compromised cardiovascular function,Hepatic impairment: Reduce dose in patients with liver cirrhosis due to increased bioavailability,Intestinal pseudo-obstruction: Rare cases reported; monitor for decreased bowel sounds or abdominal distension
Rebound hypertension upon abrupt discontinuation; sedation and drowsiness; potential for orthostatic hypotension; caution in patients with severe coronary insufficiency or cerebrovascular disease.
Hypersensitivity to nimodipine or any component of the formulation,Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin) or inducers (e.g., rifampin, phenytoin, carbamazepine)
Known hypersensitivity to guanabenz; patients with severe hepatic or renal impairment.
Avoid grapefruit juice and grapefruit products as they inhibit CYP3A4 and increase nimodipine levels. Avoid high-fat meals as they may decrease absorption.
Avoid grapefruit and grapefruit juice as they may increase quinine levels. Take with a full glass of water. May be taken with meals to reduce nausea.
Teratogenicity not established in humans; animal studies show no fetal harm. Use only if maternal benefit outweighs risk. First trimester: avoid unless essential. Second/third trimesters: potential for maternal hypotension and reduced uteroplacental perfusion.
Pregnancy Category X. Anoquan is contraindicated in all trimesters. In the first trimester, there is a high risk of major cardiac malformations and neural tube defects. Second and third trimester exposure is associated with fetal nephrotoxicity, oligohydramnios, and premature closure of the ductus arteriosus.
Excreted in breast milk; M/P ratio unknown. Use with caution; monitor infant for hypotension and bradycardia.
Excreted in human milk. M/P ratio not determined. Avoid breastfeeding due to potential for serious adverse reactions in the nursing infant, including renal impairment and electrolyte disturbances.
No standard dose adjustments established. Monitor for hypotension; consider dose reduction if severe maternal hypotension occurs.
Anoquan is contraindicated in pregnancy; no dose adjustments are recommended because use during pregnancy is not advised.
Administer via central line to avoid phlebitis; titrate slowly to avoid hypotension; monitor for bradycardia and heart block; use nifedipine (dihydropyridine) with caution in patients with hepatic impairment due to CYP3A4 metabolism.
ANOQUAN (quinine sulfate) is used for uncomplicated Plasmodium falciparum malaria. Monitor for cinchonism (tinnitus, headache, nausea). Avoid in G6PD deficiency due to hemolysis risk. Correct hypoglycemia frequently. Use with caution in atrial fibrillation due to QT prolongation.
Take exactly as prescribed, do not skip doses.,Avoid grapefruit juice and grapefruit products during treatment.,Report any unusual bleeding, bruising, or signs of infection immediately.,Do not drive or operate heavy machinery if you feel dizzy or lightheaded.,Store capsules at room temperature away from moisture and heat.
Take with food to reduce gastrointestinal upset.,Complete full course even if symptoms improve.,Report ringing in ears, confusion, or vision changes.,Avoid driving if dizziness or visual disturbances occur.,Inform doctor of any history of G6PD deficiency or cardiac arrhythmias.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NIMOTOP vs ANOQUAN, answered by our medical review team.
NIMOTOP is a Calcium Channel Blocker that works by Nimodipine is a dihydropyridine calcium channel blocker that selectively inhibits calcium influx into vascular smooth muscle cells, leading to vasodilation. It has a preferential effect on cerebral arteries, reducing the incidence of vasospasm following subarachnoid hemorrhage.. ANOQUAN is a Local Anesthetic that works by Guanabenz is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brain, leading to decreased peripheral vascular resistance and lowered blood pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NIMOTOP and ANOQUAN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NIMOTOP is: 60 mg orally every 4 hours for 21 days, initiated within 96 hours of subarachnoid hemorrhage. If unable to swallow, 0.5 mg/h continuous IV infusion via central line; increase to 1 mg/h after 2 hours if tolerated, continue for up to 21 days.. The standard adult dose of ANOQUAN is: 100 mg orally twice daily. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NIMOTOP and ANOQUAN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NIMOTOP is classified as Category C. Teratogenicity not established in humans; animal studies show no fetal harm. Use only if maternal benefit outweighs risk. First trimester: avoid unless essential. Second/third trim. ANOQUAN is classified as Category C. Pregnancy Category X. Anoquan is contraindicated in all trimesters. In the first trimester, there is a high risk of major cardiac malformations and neural tube defects. Second and . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.